Immunochemotherapy combined with antiangiogenic

DRUG2 trials

Sponsors

Tang-Du Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Conditions

Anti AngiogenesisLiver Cancer, AdultNon-Small Cell Lung Cancer

Phase 2

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

Not yet recruitingNCT06475755

Tang-Du HospitalAnti Angiogenesis, Non-Small Cell Lung Cancer

Start: 2024-06-30End: 2027-12-31Target: 178Updated: 2024-06-26

Unknown Phase

Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma

RecruitingNCT06777628

IRCCS Azienda Ospedaliero-Universitaria di BolognaLiver Cancer, Adult

Start: 2024-09-15End: 2028-10-15Target: 100Updated: 2025-01-16